Abbott Laboratories (ABT)
Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Abbott to Acquire Exact Sciences for $21 Billion
Abbott agreed to acquire Exact Sciences for $105 a share, representing a total equity value of about $21 billion.
Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.
Abbott Laboratories agrees to buy the cancer screening company in a cash deal.
Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories
A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report?
Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
Goldman Sachs Says US Stocks Could Lag for 10 Years: 5 Strong Buy Value Dividend Ideas
Goldman Sachs has projected that U.S. stocks will deliver lackluster returns over the next decade primarily due to two key factors: extreme market concentration and elevated valuations.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Goldman Sachs Still Says Sell-Off Coming – 5 Safe Conviction List Picks
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.
Abbott Laboratories' October Price Plunge Is a Signal to Buy
Abbott Laboratories' NYSE: ABT October price plunge is a signal to buy, as analyst and institutional trends suggest they, too, will be buying the stock. Analyst trends revealed by MarketBeat data include increasing coverage with newly initiated ratings appearing within days of the Q3 earnings release.
